...
Andrew TaylorJuly 13, 2023

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Loading...
Loading...2 min read

Unlocking the Future of Life Sciences Research with AI, LLMs and Knowledge Graphs

In the world of life sciences, we’re standing at the edge of a transformative era. The last decade has seen machine learning carve out significant advancements, enabling experts to predict protein interactions and design molecules with unprecedented precision. 

Yiannis Kiachopoulos

July 17, 2023

Loading...5 min read

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Andrew Taylor

July 13, 2023

Loading...3 min read

Identifying Targets in Gastrointestinal Stromal Tumors

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.

Andrew Taylor

July 12, 2023

Filter by:

Biotech

Yiannis Kiachopoulos • July 17, 2023

Unlocking the Future of Life Sciences Research with AI, LLMs and Knowledge Graphs

In the world of life sciences, we’re standing at the edge of a transformative era. The last decade has seen machine learning carve out significant advancements, enabling experts to predict protein interactions and design molecules with unprecedented precision. 

Andrew Taylor • May 26, 2023

From AI to Impact: How GPT Applications are Accelerating Drug Discovery

Causaly cofounders Yiannis Kiachopoulos and Artur Saudabayev hosted a webinar, “From AI to Impact”, in April 2023, exploring the transformative power of AI and GPT applications in early drug discovery. During this captivating session, they demonstrated how Causaly combines visual evidence with high precision knowledge graphs to answer complex research questions in mechanistic biology.   

Artur Saudabayev • February 21, 2023

How LLMs like ChatGPT impact Causaly’s approach to biomedical knowledge discovery and acquisition

At Causaly, we stay close to the developments in the foundational natural language processing technologies and broader AI to understand where we stand with both academic and industrial state-of-the-art.

Andrew Taylor • June 29, 2022

How AI is redefining hypothesis generation in pharma research

It is widely recognized that the Scientific Method is fundamental for discovering new medicines. We’re all familiar with the process: a researcher poses a question, such as what causes a specific disease, then gathers all relevant information that is known about their question. Upon digesting this information, they formulate a hypothesis and design experiments to […]

Trending

Yiannis Kiachopoulos • July 17, 2023

Unlocking the Future of Life Sciences Research with AI, LLMs and Knowledge Graphs

In the world of life sciences, we’re standing at the edge of a transformative era. The last decade has seen machine learning carve out significant advancements, enabling experts to predict protein interactions and design molecules with unprecedented precision. 

Andrew Taylor • July 13, 2023

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Andrew Taylor • July 12, 2023

Identifying Targets in Gastrointestinal Stromal Tumors

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.

Andrew Taylor • July 11, 2023

Exploring the Role of CD36 in Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic steatohepatitis (NASH) is a progressive liver condition characterized by inflammation, cell damage and fibrosis. NASH affects up to 6% of the United States population, and is becoming a significant health concern. Statistics indicate that up to 10% of individuals diagnosed with NASH will develop cirrhosis, causing permanent liver damage.

Andrew Taylor • July 6, 2023

Hormone Biomarkers for Alzheimer’s Disease: Corticosterone vs. Cortisol

Alzheimer’s disease (AD) is the most prevalent form of dementia. An estimated 6.5 million Americans aged 65 and older are living with Alzheimer’s dementia, a figure which is projected to soar to around 14 million by 2060. Current treatments only offer temporary symptomatic relief, highlighting the importance of AD research.

Andrew Taylor • June 29, 2023

HLA-DQA1 as a Target for Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) is a life-threatening respiratory condition caused by airway obstruction. It ranks among the top global causes of death, with over 200 million cases and 3 million deaths reported in 2019.

Andrew Taylor • June 27, 2023

Perforin (PRF1) as An Emerging Target for Type 1 Diabetes

Diabetes is a complex metabolic disorder which disrupts the balance of blood sugar in the body, affecting over 400 million people worldwide.¹ According to the World Health Organization (WHO), around 1.5 million deaths each year are directly attributable to diabetes, highlighting the critical need for research into this disease.

Andrew Taylor • June 19, 2023

Exploring Diagnostic Biomarkers for Sickle Cell Disease

Since the 1950s, more than 500 biomarkers for SCD have been reported in the literature, according to Causaly data. Comparing this to more common blood diseases such as leukemia, which has over 10x more biomarkers reported, highlights the significant unmet need in the rare disease research.

Andrew Taylor • June 15, 2023

Target Identification and Prioritization: A Kidney Cancer Use Case

Dive into groundbreaking research on Renal Cell Cancer, the most common kidney cancer in adults. Our blog explores innovative strategies for target identification, prioritization, and how these contribute to preventing and tackling this disease.

Andrew Taylor • May 30, 2023

Exploring the Latest Developments in Multiple Sclerosis: A 5-Year Overview

As we celebrate World MS Day on 30th May 2023, it’s a great opportunity to reflect on the significant strides that have been made in MS research over the past 5 years.

Andrew Taylor • May 26, 2023

From AI to Impact: How GPT Applications are Accelerating Drug Discovery

Causaly cofounders Yiannis Kiachopoulos and Artur Saudabayev hosted a webinar, “From AI to Impact”, in April 2023, exploring the transformative power of AI and GPT applications in early drug discovery. During this captivating session, they demonstrated how Causaly combines visual evidence with high precision knowledge graphs to answer complex research questions in mechanistic biology.   

Andrew Taylor • May 22, 2023

Strong growth in autoimmune drug target discovery in 2022

Two targets were chosen for their novelty – transcription factor CEBPB and transport protein MX2, both reported to be associated to Lupus in 2022.

Andrew Taylor • May 18, 2023

TLR7: A promising drug target for lupus

Toll-like receptor 7 (TLR7) has long been associated with the autoimmune disease, lupus. Genetic polymorphisms that result in higher TLR7 expression are associated with increased risk of developing lupus. Aberrant signaling from the protein, which senses single-stranded RNA viruses, is thought to be a mechanism driving the disease: TLR7 drives B cells to produce ‘auto-antibodies’. […]

Andrew Taylor • May 5, 2023

Momentum builds in lupus R&D

Lupus is an autoimmune disease which affects about 1 in 1000 people, which commonly causes joint pain, skin rashes and tiredness.

Maria Tella • March 3, 2023

Insights from our talk at Biomarkers 2023: The use of human-centric AI in biomarker identification in Oncology and Immunology

Biomarkers 2023 was held in Manchester, UK on the 27th and 28th of February. The event brought together a diverse group of experts, across pharma, biotech, and academic institutions.

Artur Saudabayev • February 21, 2023

How LLMs like ChatGPT impact Causaly’s approach to biomedical knowledge discovery and acquisition

At Causaly, we stay close to the developments in the foundational natural language processing technologies and broader AI to understand where we stand with both academic and industrial state-of-the-art.

Andrew Taylor • August 17, 2022

Why poor target validation is costing pharmaceutical businesses millions

It has been well documented that only 1 out of 10 compounds that enter clinical trials makes it to market¹. That is an astonishing 90% failure rate. It is hard to imagine hiring a lawyer or doctor or any professional who fails so often. Yet in our industry, it remains the norm.

Maria Tella • June 30, 2022

Knowledge discovery reimagined: finding new hypotheses with Causaly Cloud

Being able to stay up to date with scientific data and efficiently extracting insights is critical to drug R&D – but currently it is a manual, time-consuming process

Maria Tella • June 30, 2022

Watch Causaly’s panel discussion from Discovery Europe

On June 9th – 10th 2022, over 400 pharma leaders came to Berlin to take part in Discovery Europe.

Andrew Taylor • June 29, 2022

How AI is redefining hypothesis generation in pharma research

It is widely recognized that the Scientific Method is fundamental for discovering new medicines. We’re all familiar with the process: a researcher poses a question, such as what causes a specific disease, then gathers all relevant information that is known about their question. Upon digesting this information, they formulate a hypothesis and design experiments to […]